Irritable bowel syndrome and functional abdominal pain syndromes: Clinical features and management

Chronic Abdominal and Visceral Pain: Theory and Practice

Volumn , Issue , 2006, Pages 357-372

  Chang, Lin ^a   Harris, Lucinda ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39149134095     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92:1282-1284.
2. Thompson WG, Longstreth GF, Drossman DA, et al. C. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, et al., eds. Rome II. The Functional Gastrointestinal Disorders, Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. McLean: Degnon Associates, 2000: 351-432.
3. Drossman DA. The functional gastrointestinal disorders and the Rome II process. In: Drossman DA, Corazziari E, Talley NJ, et al., eds. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment. A Multinational Consensus. McLean, VA: Degnon Associates, 2000: 1-29.
4. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131.
5. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99:409-415.
6. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38:1569-1580.
7. Talley NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142:76-83.
8. Talley NJ, O'Keefe EA, Zinsmeister AR, et al. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 1992; 102:895-901.
9. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005; 3:717-725.
10. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002; 123:1686-1701.
11. Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816-2824.
12. Saito YA, Talley NJ, Melton L, et al. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003; 15:687-694.
13. Coffin B, Dapoigny M, Cloarec D, et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004; 28:11-15.
14. van der Horst HE, van Dulmen AM, Schellevis FG, et al. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel syndrome? Gut 1997; 41:669-674.
15. Taub E, Cuevas JL, Cook EW, et al. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995; 40:2647-2655.
16. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42:690-695.
17. Lee OY, Mayer EA, Schmulson M, et al. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001; 96:2184-2193.
18. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13:1149-1159.
19. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52:671-676.
20. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15:1655-1666.
21. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39:119-126.
22. Heitkemper MM, Jarrett M. Patterns of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology 1992; 102:505-513.
23. Whitehead WE, Cheskin LJ, Heller BR, et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990; 98:1485-1489.
24. Heitkemper MM, Cain KC, Jarrett ME, et al. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol 2003; 98:420-430.
25. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124:1738-1747.
26. Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107:1040-1049.
27. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees Prevalence, demographics, and clinical correlates. Dig Dis Sci 1993; 38:1581-1589.
28. Drossman DA, Li Z, Leserman J, et al. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996; 110:999-1007.
29. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109:1736-1741.
30. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500-1511.
31. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96:3122-3129.
32. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98:600-607.
33. Martin BC, Ganguly R, Pannicker S, et al. Utilization patterns and net direct medical cost to med-icaid of irritable bowel syndrome. Curr Med Res Opin 2003; 19:771-780.
34. Aston-Jones G, Rajkowski J, Kubiak P, et al. Role of the locus coeruleus in emotional activation. Prog Brain Res 1996; 107:379-402.
35. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:997-1005.
36. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126:1665-1673.
37. Whitehead WE, Palsson O, Jones KR. Systemic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 2002; 122:1140-1156.
38. Whitehead WE, Winget C, Fedoravicius AS, et al. Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982; 27:202-208.
39. Whorwell PJ, Lupton EW, Erduran D, et al. Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. Gut 1986; 27:1014-1017.
40. Chang L. The association of functional gastrointestinal disorders and fibromyalgia. Eur J Surg 1998; 583:32-36.
41. Chang L. Extraintestinal manifestations and psychiatric illness in IBS: is there a link? In: Holtmann G, Talley NJ, eds. Gastrointestinal Inflammation and Disturbed Gut Function: The Challenge of New Concepts. Dordrecht, The Netherlands: Kluwer Academic, 2003:10-16.
42. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999; 107:12S-19S.
43. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17:685-701.
44. Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002; 24:675-689.
45. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119:654-660.
46. Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004; 164:1773-1780.
47. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 2003; 3:S3-S11.
48. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97:S1-S5.
49. Drossman DA, Corazziari E, Talley NJ, et al. ROME II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. McLean, VA: Degnon Associates, 2000.
50. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome Criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912-2917.
51. Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome: prognosis and diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985; 20:415-418.
52. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1:963-965.
53. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122:107-112.
54. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45:II43-II47.
55. Cash BD, Schoenfeld P, Chew WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002; 97:2812-2819.
56. Tolliver BA, Jackson MS, Jackson KL, et al. Does lactose maldigestion really play a role in the irritable bowel? J Clin Gastroenterol 1996; 23:15-17.
57. Newcomer AD, McGill DB, Thomas PJ, et al. Tolerance to lactose among lactase-deficient American Indians. Gastroenterology 1978; 74:44-46.
58. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1-4.
59. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001; 358:1504-1508.
60. Hin H, Bird G, Fisher P, et al. Coeliac disease in primary care: case finding study. BMJ 1999; 318:164-167.
61. Holt R, Darnley SE, Kennedy T, et al. Screening for coeliac disease in patients with clinical diagnosis of irritable bowel syndrome. Gastroenterology 2001; 120:A-757.
62. Sanders DS, Patel D, Stephenson TJ, et al. A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol 2003; 15:407-413.
63. Shahbazkhani B, Forootan M, Merat S, et al. Coeliac disease presenting with symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18:231-235.
64. Spiegel BM, DeRosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126:1721-1732.
65. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-3506.
66. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98:412-419.
67. Walters B, Vanner SJ. Dectection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100:1566-1570.
68. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53:1459-1464.
69. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95:232-241.
70. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133:136-147.
71. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97:S7-S26.
72. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125:19-31.
73. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13:15-30.
74. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002; 51:i81-i86.
75. Clemens CH, Samsom M, van Berge Henegouwen GP, et al. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2002; 16:993-1002.
76. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12:849-855.
77. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised placebo-controlled trial. Lancet 2000; 355:1035-1040.
78. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161:1733-1740.
79. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96:2662-2670.
80. Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004; 2:675-682.
81. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13:1419-1427.
82. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100:115-123.
83. Chey WD, Inadomi JM, Booher AM, et al. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100:1237-1242.
84. 3 receptor antagonist alosetron. Gastroenterology 2002; 123:969-977.
85. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006. In press.
86. Bradette M, Moennikes H, Carter F, et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology 2004; 126:A-42.
87. Coremans G, Clouse RE, Carter F, et al. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D). Gastroenterology 2004; 126:A-643.
88. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118:463-468.
89. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16:1877-1888.
90. Appel-Dingemanse S, Horowitz A, Campestrini J, et al. The pharmacokinetics of the novel promo-tile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young. Aliment Pharmacol Ther 2001; 15:937-944.
91. Lefkowitz M, Ruegg P, Dunger-Baldauf C, et al. Validation of a global relief measure in clinical trials of irritable bowel syndrome with tegaserod. Gastroenterology 2000; 188:A145.
92. Tougas G, Snape WJ Jr., Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16:1701-1708.
93. Cole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004; 99:486-491.
94. Meyers NL, Palmer RMJ, George A. Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase IIb study in the UK primary healthcare setting. Gastroenterology 2004; 126:A-640.
95. Camilleri M, McKinzie S, Fox J, et al. Renzapride accelerates colonic transit and improves bowel function in constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology 2004; 126:A-642.
96. Henderson JC, Palmer RMJ, Meyers NL, et al. A phase IIb clinical study of renzapride in mixed symptom (alternating) irritable bowel syndrome. Gastroenterology 2004; 126:A-644.
97. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997; 41:394-398.
98. Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76:105-114.
99. Morgan V, Pickens D, Gautam S, et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54:601-607.
100. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124:303-317.
101. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99:914-920.
102. Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1:111-121.
103. Pimentel M, Park S, Kong Y, et al. Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Am J Gastroenterol 2005; 100:S324.
104. Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280:1585-1589.
105. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19:271-279.
106. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904.
107. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17:687-696.
108. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551.
109. Forbes A, Jackson S, Walter C, et al. Acupuncture for irritable bowel syndrome: a blinded placebo-controlled trial. World J Gastroenterol 2005; 11:4040-4044.
110. Rohrbock RB, Hammer J, Vogelsang H, et al. Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol 2004; 99:1990-1997.
111. Xing J, Larive B, Mekhail N, et al. Transcutaneous electrical acustimulation can reduce visceral perception in patients with the irritable bowel syndrome: a pilot study. Altern Ther Health Med 2004; 10:38-42.
112. Lackner JM, Mesmer C, Morley S, et al. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004; 72:1100-1113.
113. Gonsalkorale WM, Miller V, Afzal A, et al. Long-term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52:1623-1629.
114. Gonsalkorale WM, Whorwell PJ. Hypnotherapy in the treatment of irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17:15-20.
115. Simren M, Ringstrom G, Bjornsson ES, et al. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom Med 2004; 66:233-238.
116. Lea R, Houghton LA, Calvert EL, et al. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:635-642.
117. Maxton DG, Whorwell PJ. Use of medical resources and attitudes to health care of patients with "chronic abdominal pain". Br J Med Econ 1992; 2:75-79.
118. Matthews PJ, Aziz Q. Functional abdominal pain. Postgrad Med J 2005; 81:448-455.
119. Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 2005; 3:397-400.